Log in

NYSEAMERICAN:OCXOncoCyte Stock Price, Forecast & News

$1.28
+0.03 (+2.40 %)
(As of 07/9/2020 04:00 PM ET)
Add
Compare
Today's Range
$1.20
Now: $1.28
$1.30
50-Day Range N/A
52-Week Range
$1.20
Now: $1.28
$3.51
Volume993,200 shs
Average Volume477,019 shs
Market Capitalization$86.04 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
OncoCyte Corporation focuses on the development and commercialization of novel and non-invasive blood and urine (liquid biopsy) diagnostic tests for the early detection of cancer. The company is developing diagnostic tests using genetic and protein markers expressed in various types of cancer. It develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancer. The company was founded in 2009 and is based in Alameda, California. OncoCyte Corporation is a subsidiary of BioTime, Inc.
Read More
OncoCyte logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.81 out of 5 stars


Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:OCX
CUSIPN/A
Phone(510) 775-0515

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Employees12
Market Cap$86.04 million
Next Earnings Date8/12/2020 (Estimated)
OptionableNot Optionable

Receive OCX News and Ratings via Email

Sign-up to receive the latest news and ratings for OCX and its competitors with MarketBeat's FREE daily newsletter.

OncoCyte (NYSEAMERICAN:OCX) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of OncoCyte?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OncoCyte in the last year. There are currently 2 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for OncoCyte.

When is OncoCyte's next earnings date?

OncoCyte is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020. View our earnings forecast for OncoCyte.

How were OncoCyte's earnings last quarter?

OncoCyte Corp (NYSEAMERICAN:OCX) announced its earnings results on Tuesday, May, 12th. The biotechnology company reported ($0.13) earnings per share for the quarter, missing analysts' consensus estimates of ($0.11) by $0.02. The biotechnology company earned $0.02 million during the quarter. View OncoCyte's earnings history.

What price target have analysts set for OCX?

4 Wall Street analysts have issued 12-month target prices for OncoCyte's stock. Their forecasts range from $2.00 to $7.50. On average, they anticipate OncoCyte's share price to reach $4.38 in the next twelve months. This suggests a possible upside of 241.8% from the stock's current price. View analysts' price targets for OncoCyte.

Has OncoCyte been receiving favorable news coverage?

News articles about OCX stock have been trending negative on Friday, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. OncoCyte earned a news sentiment score of -2.3 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the next few days. View the latest news about OncoCyte.

Who are some of OncoCyte's key competitors?

What other stocks do shareholders of OncoCyte own?

Who are OncoCyte's key executives?

OncoCyte's management team includes the following people:
  • Mr. William Annett, Pres, CEO & Director (Age 65)
  • Mr. Mitchell S. Levine, Chief Financial Officer
  • Dr. Lyndal K. Hesterberg, Chief Scientific Officer
  • Mr. Albert P. Parker II, Chief Operating Officer
  • Dr. Michael D. West, Scientific Advisor, Co-CEO of Biotime,Inc. & Pres of Biotime,Inc. (Age 66)

What is OncoCyte's stock symbol?

OncoCyte trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "OCX."

How do I buy shares of OncoCyte?

Shares of OCX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is OncoCyte's stock price today?

One share of OCX stock can currently be purchased for approximately $1.28.

How big of a company is OncoCyte?

OncoCyte has a market capitalization of $86.04 million. OncoCyte employs 12 workers across the globe.

What is OncoCyte's official website?

The official website for OncoCyte is www.oncocyte.com.

How can I contact OncoCyte?

OncoCyte's mailing address is 1010 Atlantic Ave Ste 102, ALAMEDA, CA 94501-1147, United States. The biotechnology company can be reached via phone at (510) 775-0515.

This page was last updated on 7/10/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.